Other

Genentech, Inc.

Osi Pharmaceuticals, Inc.

David A Eberhard

John D Haley

Graeme Griffin

Lukas A Amler

Avi J Ashkenazi

Germaine G Fuh

Jo-Anne Hongo

Chingwei Vivian Lee

Dorothy French

Gretchen Frantz

Robert Maurice Pitti

Robert L Yauch

Lukas C Amler

Liliana Soroceanu

Beni B Wolf

Heidi Ackerly

Scot A Masters

Evgeny Varfolomeev

Helga A Raab

The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided.

Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors

The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.

Compositions and methods relating to STOP-1

Growing community of inventors

San Francisco, CA, United States of America

David A Eberhard